The association between hypergammaglobulinaemia and raised serum viscosity has been recognised for more than 40 years. Waldenstrom (1944) described three patients in whom macroglobulinaemia was associated with increased serum viscosity, and even earlier than this there had been reports of raised plasma viscosity in myelomatosis (Albers, 1937) . Since these early reports many of the clinical features of macroglobulinaemia have been recognised to be a direct consequence of the increased plasma viscosity, and in 1965 Fahey and his colleagues defined the condition now known as the hyperviscosity syndrome (Fahey et al., 1965) . Initially it was believed that the hyperviscosity syndrome (HVS) was almost invariably associated with Waldenstrom's macroglobulinaemia and that it was a rare complication of myelomatosis. During the last few years, however, it has become increasingly recognised as a complication of certain types of myelomatosis (Preston et al., 1978; .
Concept of viscosity
Viscosity is best considered as the resistance offered by a liquid to attempts to change its shape (Phillips and Harkness, 1976) . It is thus a measure of its resistance to flow. It is defined as the ratio of shear stress to shear rate. Shear stress is the tangential force exerted across a unit area between two parallel planes of the fluid, unit distance apart, with one plane moving at unit velocity relative to the other. where Q is the flow rate, ZP is the pressure gradient, 1 is the tube length, r is the tube radius, and X is the viscosity. Although Poiseuille's biological studies were concerned primarily with blood flow through the mesenteric circulation his formula was derived from studies of the dynamics of the flow of water through capillary tubes. For simple fluids the relationship between shear stress and shear rate is constant, and such fluids are described as having Newtonian flow characteristics. Blood, however, does not behave as a simple fluid and its anomalous flow characteristics are described as non-Newtonian. Blood can be considered as a suspension of erythrocytes in plasma, and it is these that are primarily responsible for the non-Newtonian behaviour of this biological fluid (Whitmore, 1968) . Unlike Newtonian fluids, in which the viscosity is independent of the rate of shear, there have been a number of reports showing that the viscosity of the blood depends on the shear rate, with non-Newtonian characteristics becoming more pronounced at low rates of shear (Phillips and Harkness, 1976; Dintenfass, 1965) .
Factors affecting blood viscosity
The haematocrit is the most important single factor influencing whole blood viscosity. Most workers agree that there is a linear relationship between the haematocrit and the logarithm of the blood viscosity (Virgilio et al., 1964; Dormandy et al., 1973) . The importance of this should be borne in mind when transfusing patients with increased blood viscosities from other causes, since the increase in haematocrit may raise the whole blood viscosity to a level associated with the clinical features of HVS. Erythrocyte flexibility is also a factor influencing blood viscosity. This may relate to the internal structure of the red cell, as in sickle-cell anaemia, but in addition there is evidence to show that red cell flexibility may be influenced by plasma fibrinogen levels. Plasma fibrinogen is another important factor influencing plasma and therefore whole blood viscosity. It also contributes to the non-Newtonian behaviour of blood with its viscosity effects becoming more prominent at low rates of shear.
Pathophysiology of HVS in paraproteinaemias
In macroglobulinaemia the raised serum viscosity relates to the physical properties of the IgM molecule, which has a molecular weight of 1 million. In addition it also has a high axial-length/width ratio which is associated with a high intrinsic viscosity of the molecule. A given concentration of IgM is consequently associated with a higher serum viscosity than that produced by the same concentration of the smaller IgG molecule (MW 160 000).
There are two main mechanisms whereby hyperviscosity effects may be produced in myelomatosis. Firstly, extremely high concentrations of serum paraprotein, regardless of class or subtype, will raise the blood viscosity to clinically significant levels. (Somer, 1975 (Preston et al., 1978 (Somer, 1975; Schwab and Fahey, 1960 (Lackner et al., 1970) . Occasionally the prothrombin time or partial thromboplastin time may be unduly prolonged, and again evidence for inhibitory activity against one or more clotting factors should be sought.
HYPERVOLAEMIA AND HVS
There have been a number of reports of increased plasma volume in patients with paraproteinaemia, and various workers have emphasised the correlation between plasma volume and serum viscosity in patients with myelomatosis and Waldenstrom's macroglobulinaemia Russell and Powles, 1978) . From what has been said it is to be expected that plasma volumes in patients with IgA myeloma and macroglobulinaemia would, in general, be greater than in patients with IgGi myeloma. This was confirmed by . The mechanism responsible for this relationship, however, is unclear. It is unlikely to relate to colloid osmotic pressure, since this is generally regarded as being inversely related to molecular weight. An important question is whether the increased plasma volume contributes to the clinicopathological features of HVS. In an attempt to study this Russell and Powles (1978) examined the relationships between plasma volume, serum viscosity, retinopathy, and a bleeding tendency in patients with myeloma and macroglobulinaemia. They concluded that the retinopathy of HVS was more closeIy related to raised viscosity levels than to hypervolaemia.
The relationship between bleeding and viscosity levels, however, is more difficult to define. These same authors showed that although the correlation between bleeding and viscosity is strong there are nevertheless patients who bleed whose blood viscosity is insufficient to be associated with a retinopathy. Russell and Powles (1978) conclude that although hypervolaemia in itself does not seem to be a critical factor it could perhaps influence the presence of symptoms when other factors causing bleeding are present, whether or not they are directly related to the high viscosity. Although the serum viscosity is often raised in patients with paraproteinaemia, irrespective of the presence or absence of HVS, some useful guide lines are available. Fahey et al. (1965) state that although there is great individual variation, no patient in their study with serum viscosities less than 4.0 had symptoms. Similarly Russell and Powles (1978) report that the retinopathy of HVS is always associated with serum viscosity levels greater than 3.8. There are inherent dangers in relying solely on serum viscosity levels for the diagnosis of HVS since the whole blood viscosity is influenced by the haematocrit and also by red cell aggregation. For these reasons it is perhaps more appropriate to measure whole blood viscosity levels at various rates of shear.
Treatment
Large amounts of paraprotein can be removed by plasmapheresis, which thus constitutes an effective method for treating HVS. The fall in paraprotein concentration is paralleled by a fall in serum viscosity, and this is often accompanied by a dramatic reversal of the patient's symptoms (Figure) . The volume of plasma which requires to be removed depends upon its initial concentration and the type of paraprotein: 80% of IgM, for example, is confined within the intravascular space compared with 40 % for IgG. Consequently plasmapheresis for macroglobulinaemia will effectively remove large concentrations of IgM and afterwards there will be only a minimal secondary rise in serum 1gM from the extravascular compartment. A single plasmapheresis for IgG myeloma, however, will be less effective since there may be an appreciable secondary rise from the extravascular space. Further plasmapheresis may then be needed.
At clinical presentation symptoms are usually satisfactorily reversed by plasmapheresis, and ade- quate control can be maintained with standard chemotherapeutic regimens. During relapse, however, the problem is much more difficult. The rapid production of new paraprotein may rapidly negate the beneficial effects of plasmapheresis. It should be remembered that patients with HVS are invariably anaemic, with hypervolaemia an important contributory factor. Thus blood transfusion may be hazardous, since the improved haematocrit may severely aggravate the clinical features of HVS by its effect on blood viscosity.
